Technical Study: Zoetis Inc., Teva Pharma Industries Ltd, Covidien plc, and Valeant Pharma Intl. Inc.

 Technical Study: Zoetis Inc., Teva Pharma Industries Ltd, Covidien plc, and
                          Valeant Pharma Intl. Inc.

PR Newswire

LONDON, August 21, 2013

LONDON, August 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Tuesday August 20, 2013, the S&P 500 ended at 1,652.35, up 0.38% and the
NASDAQ composite closed at 3,613.59, up 0.68%. Shares in healthcare sector
companies mostly ended on a higher note, tracking gains in the broader market.
The movers in the sector included Zoetis Inc. (NYSE: ZTS), Teva Pharmaceutical
Industries Ltd (NYSE: TEVA), Covidien PLC (NYSE: COV), and Valeant
Pharmaceuticals International Inc. (NYSE: VRX). AAAResearchReports.com free
coverage on ZTS, TEVA, COV, and VRX is available upon registration at:

http://www.aaaresearchreports.com/register/

Zoetis Inc.'s stock rose sharply on Tuesday as the broader market edged
higher. The company's shares traded between $29.71 and $30.41 before closing
the day 1.21% higher at $30.23. A total of 3.80 million shares were traded,
which is significantly below the daily average volume of 9.14 million. The
company's stock has gained 0.70% in the previous three trading sessions,
outperforming the S&P 500 which has declined by 0.54% during the same period.
Download free technical research on ZTS by signing up at:

http://www.AAAResearchReports.com/ZTS082113.pdf

Shares in Teva Pharmaceutical Industries Ltd fell sharply on Tuesday,
extending losses from previous trading sessions. The company's shares ended
the day at $39.13, down 1.16%, after fluctuating between $39.10 and $39.69. A
total of 3.78 million shares were traded, which is marginally above the daily
average volume of 3.72 million. The company's shares have dropped 2.42% in the
last one month and 2.64% in the last three months, underperforming the S&P 500
during the same period. Furthermore, Teva Pharmaceutical Industries Ltd's
stock is trading marginally above its 200-day moving average of $39.11.
Register now and get access to free analysis on TEVA at:

http://www.AAAResearchReports.com/TEVA082113.pdf

On Tuesday, Covidien PLC's stock traded between $60.76 and $61.20 before
finishing the day 0.10% higher at $60.96. A total of 1.70 million shares were
traded, which is below the daily average volume of 2.53 million. The company's
shares have gained 2.25% in the last three months, outperforming the S&P 500
which has fallen by 0.84% during the same period. Additionally, Covidien PLC's
shares are trading above their 50-day and 200-day moving averages. Sign up and
read our complimentary report on COV at:

http://www.AAAResearchReports.com/COV082113.pdf

Shares in Valeant Pharmaceuticals International Inc. ended higher on Tuesday,
tracking gains in the broader market. The company's shares vacillated between
$100.78 and $102.45 before finishing the day 0.47% higher at $101.53. A total
of 0.80 million shares were traded, which is below the daily average volume of
1.89 million. The stock has fallen 1.36% in the previous three trading
sessions. Despite recent losses, the company's shares have gained 11.82% in
the last one month and 34.69% in the last three months, outperforming the S&P
500 which has declined by 2.35%and 0.84% during the same periods. The free
report on VRX can be downloaded by signing up now at:

http://www.AAAResearchReports.com/VRX082113.pdf

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA ® charterholder. However, we are only human
    and are prone to make mistakes. If you notice any errors or omissions,
    please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://www.AAAresearchreports.com

SOURCE AAA Research Reports

Contact: Media Contact: Peter F. Jones, Phone #: +1-(646)-396-9126, Email ID:
info@aaaresearchreports.com
 
Press spacebar to pause and continue. Press esc to stop.